Table 2.
Comparison of the questionnaires between AIBD patients and non-AIBD controls
| AIBD patients | Non-AIBD controls | P value | |
|---|---|---|---|
| (n = 25) | (n = 24) | ||
| SF-36 | 59.64 ± 17.32 | 79.04 ± 17.97 | < 0.001 |
| MSC | 61.56 ± 19.78 | 77.54 ± 19.90 | 0.007 |
| PCS | 57.96 ± 20.56 | 80.88 ± 19.11 | < 0.001 |
| Physical functioning | 83.80 ± 15.63 | 92.08 ± 10.62 | 0.036 |
| Physical role functioning | 33.00 ± 42.52 | 83.33 ± 38.07 | < 0.001 |
| Bodily pain | 74.96 ± 24.98 | 86.58 ± 21.43 | 0.088 |
| General health perceptions | 45.00 ± 21.11 | 55.42 ± 23.82 | 0.112 |
| Vitality | 63.00 ± 16.77 | 59.38 ± 26.43 | 0.568 |
| Social role functioning | 68.28 ± 21.61 | 86.96 ± 19.03 | 0.002 |
| Emotional role functioning | 47.92 ± 47.21 | 80.50 ± 35.36 | 0.009 |
| Mental health | 65.20 ± 21.43 | 73.00 ± 17.47 | 0.170 |
| HADS | |||
| Anxiety | 5.96 ± 3.40 | 3.75 ± 3.23 | 0.024 |
| Depression | 7.44 ± 4.00 | 6.13 ± 4.49 | 0.284 |
| PSQI | 6.68 ± 3.96 | 7.54 ± 4.45 | 0.478 |
| PSQI level, n (%) | 0.355 | ||
| Normal (scores < 5) | 9 (36.0%) | 5 (20.8%) | |
| Abnormal (scores ≥ 5) | 16 (64.0%) | 19 (79.2%) | |
| HAQ-DI | 0.16 ± 0.47 | 0.04 ± 0.20 | 0.264 |
SF-36 Medical Outcomes Study 36-Item Short Form questionnaire, PCS Physical component summary, MCS Mental component summary, HADS Hospital Anxiety and Depression Scale, PSQI Pittsburgh Sleep Quality Index, HAQ-DI Health Assessment Questionnaire-Disability Index, AIBD Autoimmune blistering skin diseases
Significant differences (P value < 0.05) are bolded